What Is The Forecast Valuation Of The Peptide And Oligonucleotide CDMO Market Projected To Reach $3.69 Billion By 2029?
Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
How Will The Peptide And Oligonucleotide CDMO Market Valuation Change Between Now And 2029?
The market size for peptide and oligonucleotide cdmo has witnessed fast-paced growth in recent years. It is projected to expand from a value of $2.16 billion in 2024 to $2.42 billion in 2025, marking a compound annual growth rate (CAGR) of 11.8%. The notable growth in the historic period can be credited to several factors, including an increase in demand for therapeutic agents, improvements in synthesis and manufacturing processes, trends in personalized medicine, regulatory guidelines, and a heightened focus on antiviral peptides and mRNA vaccines, which underscore the potential of oligonucleotides in vaccine development.
In the coming years, the peptide and oligonucleotide cdmo market is predicted to witness an accelerated growth, escalating to a worth of $3.69 billion in 2029 with a compound annual growth rate (CAGR) of 11.2%. A surge in the requirements for personalized healthcare solutions, developments in biotech field, broadening applications, greater rate of outsourcing, and the rising prevalence of chronic illnesses contribute to this anticipated growth. The forecasted period also anticipates key trends such as customized therapies, technological evolution, challenges in quality management, international growth, and degrees of collaboration within biopharmaceutical firms increasing.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp
What Growth-Enabling Forces Are Impacting The Peptide And Oligonucleotide CDMO Market?
The advancement of personalized medicine, which individualizes medical decisions and treatments based on qualities like genetics, environment, and lifestyle, is poised to boost the growth of peptide and oligonucleotide CDMO markets. This rise in personalized medicine comes as a result of factors such as improved genomic technologies, deeper comprehension of disease mechanisms at the molecular level, and a need for more effective and targeted treatments customized to each patient’s unique genetic profile and medical history. In the realm of personalized medicine, the importance of peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) cannot be understated, as they are responsible for the creation of bespoke therapeutic peptides and oligonucleotides designed for individual patients. In a case reported in February 2024 by the Personalized Medicine Coalition, a UK-based advocacy group for the implementation of personalized medicine, the FDA’s Center for Drug Evaluation and Research (CDER) greenlighted 16 new personalized treatments for patients suffering from rare diseases, marking a considerable increase from the 6 approved in 2022. Hence, it’s clear that the ongoing surge in personalized medicine applications fuels the expansion of the peptide and oligonucleotide CDMO market.
How Is The Peptide And Oligonucleotide CDMO Market Segmented Across Key Categories?
The peptide and oligonucleotide cdmo market covered in this report is segmented –
1) By Product: Peptides, Oligonucleotides
2) By Service Type: Contract Development, Contract Manufacturing,
3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications
4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Others End Users
Subsegments:
1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services
2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services
What Key Trends Are Driving Growth In The Peptide And Oligonucleotide CDMO Market?
Leading firms in the peptide and oligonucleotide CDMO sector are establishing strategic alliances to improve their services, broaden their technological base, and enhance their market penetration. Partnerships in peptide development and production entail cooperative contracts between two entities aiming to develop and produce peptide-based treatments. For example, in May 2023, PolyPeptide Group AG, an American CDMO, teamed up with Numaferm GmbH, a biotech firm based in Germany, for peptide development and manufacturing. The objective of this partnership is to leverage PolyPeptide’s cGMP manufacturing capacities and market penetration, and Numaferm’s proficiency in sustainable peptide production and biochemical manufacturing platforms. The collaboration aims at joint exploration of potential peptide candidates for more eco-friendly production of peptide-based APIs.
Which Companies Are Contributing Significantly To The Peptide And Oligonucleotide CDMO Market Growth?
Major companies operating in the peptide and oligonucleotide CDMO market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd., Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc., ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.
Access The Complete Report Here:
Which Region Dominates The Peptide And Oligonucleotide CDMO Market Today?
North America was the largest region in the peptide and oligonucleotide CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=15892&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
